Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Common Equity: 2022-2024

Historic Common Equity for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to $401.5 million.

  • Centessa Pharmaceuticals' Common Equity fell 39.58% to $301.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $301.6 million, marking a year-over-year decrease of 39.58%. This contributed to the annual value of $401.5 million for FY2024, which is 69.97% up from last year.
  • According to the latest figures from FY2024, Centessa Pharmaceuticals' Common Equity is $401.5 million, which was up 69.97% from $236.2 million recorded in FY2023.
  • Over the past 5 years, Centessa Pharmaceuticals' Common Equity peaked at $401.5 million during FY2024, and registered a low of $236.2 million during FY2023.
  • In the last 3 years, Centessa Pharmaceuticals' Common Equity had a median value of $336.2 million in 2022 and averaged $324.7 million.
  • Its Common Equity has fluctuated over the past 5 years, first declined by 29.72% in 2023, then spiked by 69.97% in 2024.
  • Centessa Pharmaceuticals' Common Equity (Yearly) stood at $336.2 million in 2022, then fell by 29.72% to $236.2 million in 2023, then surged by 69.97% to $401.5 million in 2024.